DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Last trade$8.14
Day change-$0.19 (-2.28%)
Day range$7.90 – $8.80
Volume129,120
Market cap$449M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$449.47M
Price / earnings
—
Price / book
11.72×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.34×
Profitability
Earnings per share
-$0.70
Return on assets
-83.39%
Return on equity
-97.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.72×
Quick ratio
6.72×
Cash ratio
0.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DMAC, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.35M
$2.5M
$2.51M
$2.6M
$2.19M
$2.49M
$1.95M
$1.9M
Research and development
$8.15M
$7.99M
$6.7M
$6.44M
$5.82M
$5.66M
$6.47M
$4.98M
Total operating expenses
$10.5M
$10.48M
$9.21M
$9.03M
$8.01M
$8.14M
$8.42M
$6.88M
Operating income
-$10.5M
-$10.48M
-$9.21M
-$9.03M
-$8.01M
-$8.14M
-$8.42M
-$6.88M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$10.13M
-$10.04M
-$8.73M
-$8.61M
-$7.69M
-$7.7M
-$7.89M
-$6.27M
Income taxes
$7K
$7K
$10K
$6K
$6K
$6K
$9K
$7K
Net income
-$10.14M
-$10.04M
-$8.74M
-$8.62M
-$7.7M
-$7.71M
-$7.9M
-$6.27M
Net income attributable to common shareholders
-$10.15M
-$10.04M
-$8.71M
-$8.62M
-$7.72M
-$7.71M
-$7.88M
-$6.27M
EBITDA
-$10.49M
-$10.47M
-$9.2M
-$9.02M
-$8M
-$8.13M
-$8.41M
-$6.87M
Basic earnings per share
-$0.19
-$0.19
-$0.17
-$0.17
-$0.18
-$0.18
-$0.18
-$0.15
Diluted earnings per share
-$0.19
-$0.19
-$0.17
-$0.17
-$0.18
-$0.18
-$0.18
-$0.15
Recent news
Company coverage with links to the original publishers.
The acute ischemic stroke market is expected to grow significantly through 2036, driven by increased symptom awareness, advances in acute stroke care, and a robust pipeline of innovative therapies. Key candidates in development include lenzocimab, DM199, milvexian, and BB-031. The US accounts for the largest market share, with approximately 1.8 million incident cases across the 7MM in 2025. Recent developments include FDA approval of tenecteplase in March 2025 and encouraging Phase 2 results for LT3001.
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.